US Patent 11077201 Immunoconjugates with an intracellularly-cleavable linkage
Patent 11077201 was granted and assigned to IMMUNOMEDICS, INC. on August, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+304 characters)
Article
Patent abstract
The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
Edits on 10 Oct, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
David M. Goldenberg0
Serengulam V. Govindan0
Sung-Ju Moon0
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 22 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
110772010
Date of Patent
August 3, 2021
0Patent Application Number
202001030
Date Filed
January 3, 2020
0Official Website
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 8 Oct, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 11077201 Immunoconjugates with an intracellularly-cleavable linkage
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11077201
Date of patent
August 3, 2021
Patent application number
20200103
Date Filed
January 3, 2020
Find more entities like US Patent 11077201 Immunoconjugates with an intracellularly-cleavable linkage
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
